 |
Cour Pharmaceutical
Last updated: July 09, 2024
John Puisis - Co-Founder, President and CEO
USA | Funding: $135.5M (+)
Website: http://www.courpharma.com/
The Cour particle platforms provide a novel and highly specific immune targeting capability which may be safely applied to severe inflammatory modulation, and immune (antigen) tolerization.
Website: http://www.courpharma.com/
The Cour particle platforms provide a novel and highly specific immune targeting capability which may be safely applied to severe inflammatory modulation, and immune (antigen) tolerization.
